Form 4: Zai Lab CFO Reports Stock Option, RSU Grants & Tax-Related Sale

Zai Lab's Chief Financial Officer, Chen Yajing, reported new grants of stock options and restricted share units, alongside a sale of American Depositary Shares to cover tax obligations.

Summary

• Zai Lab's Chief Financial Officer, Chen Yajing, reported several transactions involving the company's American Depositary Shares (ADSs), stock options, and Restricted Share Units (RSUs).
• On March 12, 2026, Chen Yajing acquired 4,258 ADSs upon the vesting of previously granted RSUs.
• On March 13, 2026, 1,703 ADSs were sold at a price of $18.628 per ADS to cover tax liabilities associated with the RSU vesting.
• Following these transactions, Chen Yajing beneficially owns 19,999 direct ADSs.
• On March 4, 2026, Chen Yajing was granted 83,160 stock options with an an exercise price of $19.27 per ADS, vesting in equal annual installments over four years starting March 4, 2027.
• Also on March 4, 2026, Chen Yajing received a new grant of 27,027 Restricted Share Units, vesting in equal annual installments over four years beginning March 4, 2027.
• An existing RSU grant saw 4,258 units vest on March 12, 2026, with the remaining 12,777 units from that grant still unvested.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting ongoing executive compensation through significant new equity grants (options and RSUs), which align the CFO's interests with long-term shareholder value, despite a routine tax-related sale.

Positives

• Grant of 83,160 stock options with an exercise price of $19.27, indicating long-term incentive alignment for the CFO.
• Grant of 27,027 Restricted Share Units, further aligning management's interests with shareholder value.
• Vesting of 4,258 Restricted Share Units, increasing direct ownership of American Depositary Shares.

Negatives

• Sale of 1,703 American Depositary Shares at $18.628 to cover tax obligations, reducing direct beneficial ownership.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that executive equity grants and tax-related sales are standard practices in the biotechnology and pharmaceutical industry, aligning executive incentives with long-term company performance and shareholder value. These transactions are routine disclosures for publicly traded companies.

Stakeholder Impact

• Shareholders: The grants of stock options and RSUs align the CFO's interests with shareholder value creation over the long term. The tax-related sale is a routine event with minimal impact.

Next Steps

• Continued vesting of 83,160 stock options in equal annual installments over four years, beginning March 4, 2027.
• Continued vesting of 27,027 Restricted Share Units in equal annual installments over four years, beginning March 4, 2027.
• Continued vesting of the remaining 12,777 Restricted Share Units from a prior grant in equal annual installments over four years, beginning March 12, 2026.

Key Dates

Keywords

Zai Lab, ZLAB, Chen Yajing, CFO, Form 4, insider transaction, stock options, restricted share units, RSU, equity compensation, executive compensation, beneficial ownership